A

Alliance Pharma PLC
LSE:APH

Watchlist Manager
Alliance Pharma PLC
LSE:APH
Watchlist
Price: 64.7 GBX
Market Cap: 356.5m GBX

Wall Street
Price Targets

APH Price Targets Summary
Alliance Pharma PLC

There are no price targets for APH.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Alliance Pharma PLC Competitors:
Price Targets
MEGA
Mega Lifesciences PCL
5% Upside
ARVN
Arvinas Inc
12% Upside
AUROPHARMA
Aurobindo Pharma Ltd
11% Upside
VENUSREM
Venus Remedies Ltd
55% Downside
000520
Samil Pharmaceutical Co Ltd
27% Upside
ACUTAAS
Acutaas Chemicals Ltd
15% Upside
603566
Pulike Biological Engineering Inc
35% Upside
SNT
Syntara Ltd
325% Upside

Revenue
Forecast

Revenue Estimate
Alliance Pharma PLC

For the last 13 years the compound annual growth rate for Alliance Pharma PLC's revenue is 11%. The projected CAGR for the next 3 years is 9%.

11%
Past Growth
9%
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Alliance Pharma PLC

For the last 13 years the compound annual growth rate for Alliance Pharma PLC's operating income is 8%. The projected CAGR for the next 3 years is 16%.

8%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Net Income
Forecast

Net Income Estimate
Alliance Pharma PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-51%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is APH's stock price target?
Not Available

APH doesn't have any price targets made by Wall Street professionals.

What is Alliance Pharma PLC's Revenue forecast?
Projected CAGR
9%

For the last 13 years the compound annual growth rate for Alliance Pharma PLC's revenue is 11%. The projected CAGR for the next 3 years is 9%.

What is Alliance Pharma PLC's Operating Income forecast?
Projected CAGR
16%

For the last 13 years the compound annual growth rate for Alliance Pharma PLC's operating income is 8%. The projected CAGR for the next 3 years is 16%.

Back to Top